Teva Pharmaceuticals USA is recalling approximately 181,456 bottles of Olmesartan Medoxomil and Hydrochlorothiazide (40 mg/25 mg) tablets, a prescription medication used to treat high blood pressure. The recall was initiated because the tablets failed dissolution testing, which means the medication may not dissolve properly in the body to release the active ingredients as intended. This defect could potentially reduce the effectiveness of the blood pressure treatment. These products were distributed nationwide in 30-count and 90-count bottles and were manufactured in Israel.
The tablets failed to meet dissolution specifications, which can prevent the medication from being absorbed correctly by the body. This may lead to uncontrolled high blood pressure, increasing the risk of cardiovascular events like heart attack or stroke if the medication does not work as expected.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.